Milford, Mass.-based SeraCare Life Sciences, a global life sciences company focusing on human diagnostics and therapeutics, has acknowledged the receipt of an unsolicited offer from MSMB Capital proposing to purchase all of the outstanding shares of SeraCare for $4.25 per share. It is anticipated that the SeraCare board of directors will review the proposal.

SeraCare's portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services.